Business Description
Oncolytics Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : CA6823108759
Total Employee Number:
29Description
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 9.19 | |||||
Equity-to-Asset | -0.8 | |||||
Debt-to-Equity | -0.07 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 3.9 | |||||
3-Year EPS without NRI Growth Rate | 3.4 | |||||
3-Year FCF Growth Rate | 10.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.65 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.52 | |||||
9-Day RSI | 60.38 | |||||
14-Day RSI | 55.72 | |||||
3-1 Month Momentum % | -15.28 | |||||
6-1 Month Momentum % | -29.9 | |||||
12-1 Month Momentum % | -25.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.35 | |||||
Quick Ratio | 1.35 | |||||
Cash Ratio | 0.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.8 | |||||
Shareholder Yield % | -18.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -391.26 | |||||
ROIC % | -3560.69 | |||||
3-Year ROIIC % | 2086.15 | |||||
ROC (Joel Greenblatt) % | -5426.38 | |||||
ROCE % | -877.91 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.77 | |||||
EV-to-Forward-EBIT | 38.45 | |||||
EV-to-EBITDA | -2.79 | |||||
EV-to-Forward-EBITDA | -2.81 | |||||
EV-to-Forward-Revenue | 44.3 | |||||
EV-to-FCF | -3.97 | |||||
Earnings Yield (Greenblatt) % | -36.1 | |||||
FCF Yield % | -24.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ONCY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Oncolytics Biotech Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.345 | ||
| Beta | 1.1822 | ||
| 3-Year Sharpe Ratio | -0.13 | ||
| 3-Year Sortino Ratio | -0.26 | ||
| Volatility % | 63.85 | ||
| 14-Day RSI | 55.72 | ||
| 14-Day ATR ($) | 0.042233 | ||
| 20-Day SMA ($) | 0.82454 | ||
| 12-1 Month Momentum % | -25.97 | ||
| 52-Week Range ($) | 0.7301 - 1.51 | ||
| Shares Outstanding (Mil) | 127.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncolytics Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncolytics Biotech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 75 days | ||
| General meeting for 2026 | 2026-08-28 10:00 | 0.86 (-0.49%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 0.82 (+2.50%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.87 (-1.33%) | ||
| Annual report for 2025 | 2026-03-30 | 0.84 (-6.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 0.84 (-6.67%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 1.14 (+4.13%) | ||
| General meeting for 2025 | 2025-08-08 10:00 | 0.92 (-1.60%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-08 | 0.92 (-1.60%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 0.92 (-1.60%) |
Show
Entries
Oncolytics Biotech Inc Frequently Asked Questions
What is Oncolytics Biotech Inc(ONCY)'s stock price today?
The current price of ONCY is $0.86. The 52 week high of ONCY is $1.51 and 52 week low is $0.73.
When is next earnings date of Oncolytics Biotech Inc(ONCY)?
The next earnings date of Oncolytics Biotech Inc(ONCY) is 2026-11-13 Est..
Does Oncolytics Biotech Inc(ONCY) pay dividends? If so, how much?
Oncolytics Biotech Inc(ONCY) does not pay dividend.
Press Release
Articles on Oncolytics Biotech Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers